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ABSTRACT
Meyer, Abby Elizabeth. MS. The University of Memphis. May 2013. Inhibitory Control
Performance in Rats Perinatally Exposed to PCBs Before and After Microinjections of
Bupropion Into Medial Prefrontal Cortex. Major Professor: Dr. Helen Sable.

Polychlorinated Biphenyls (PCBs) are a very stable environmental contaminant. Perinatal
exposure to PCBs leads to a depletion of dopamine (DA) in the medial prefrontal cortex
(mPFC). Dopamine depletion in mPFC, in turn, leads to inhibitory-control problems.
This study investigated the link between perinatal exposure to PCBs, the effect of this
exposure on DA levels in the mPFC, and inhibitory-control problems during adulthood
using a rodent model. Significant effects of PCB exposure were found for physiological
measures and on inhibitory control performance using a differential reinforcement of low
rates of responding task (DRL) task. Microinjections of bupropion into mPFC appeared
to dose-dependently improve performance, but this effect was not influenced by PCB
dose. Thus, it appears drugs administered to enhance/sustain the action of DA released
from the presynaptic terminal provide little therapeutic value at correcting the inhibitory
control deficits that occur following perinatal exposure to PCBs.
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Chapter 1: Introduction
The History of PCBs
Polychlorinated biphenyls (PCBs) are a ubiquitous man-made substance that has
been shown to have numerous health effects on biological systems. Each PCB molecule
contains two biphenyl rings that are held together by strong carbon bonds. Due to the
stability of the chemical structure of this compound, PCBs were used in industry for
several decades in the manufacturing of fire and heat resistant products, including
dielectrics in transformers and capacitors, cooling fluids in hydraulic systems, pesticides,
paints, copy paper, adhesives, and plastics (Erikson, 1997; Fonnum & Mariussen, 2009;
Robertson & Ludewig, 2011). As versatile and useful as the substance was to industry, it
became evident that workers’ exposure to PCBs caused numerous health problems,
including cancers and other deleterious effects on the reproductive, nervous, and
endocrine systems (ATSDR, 2000; Langer et al., 2009; Rosin & Martin, 1981; Sazonova
et al., 2011; Schantz, Seo, Wong, & Pessah, 1997; Selvakumar et al., 2012; Shen et al.,
2011; Vitalone et al., 2010). Due to these health concerns, the manufacturing of PCBs
was banned by the United States Toxic Substances Control Act (TCSA) in 1977;
however, PCBs are still produced in other countries, including North Korea and Russia
(Berger et al., 2001) and also in the United States as an unintentional by-product in the
manufacturing process of pigments in certain dyes and paints (Grossman, 2013). As this
substance was, and still is, released into our environment in the form of industrial waste,
the health effects of exposure to PCBs extend to include the general population with a
significant impact on pregnant mothers and their children (Jackson, Lynch, Kostyniak,
McGuinness, & Louis, 2010; Lonky, Reihman, Darvill, Mather Sr., & Daly, 1996; Louis
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et al., 2008; Murphy, Gollenberg, Louis, Kostyniak, & Sundaram, 2010; Peterson,
Theobald, & Kimmel, 1993; Robertson & Ludewig, 2011). Government regulations of
this chemical have since greatly decreased the dangers posed to industrial workers, but
the threat of PCB exposure to the general population continues to this day due to the
stability of the compound in the environment.
Each of the numbered positions in Figure 1A indicates a possible location for
chlorine substitution on the biphenyl molecule (hence the name, polychlorinated
biphenyls). Hydrogen atoms attach to the positions along the biphenyl molecule by
default, and the molecule assumes a planar configuration with both of the benzene
molecules in the same plane. There are 209 possible combinations for chlorine
substitutions, and these different combinations are known as congeners (Hansen, 1999).
When chlorine atoms take the place of hydrogen, the shape of the molecule can change.
Specifically, to remain in a planar conformation the molecule must have zero or one
ortho chlorines (positions 2, 2’, 6, or 6’), two meta chlorines (positions 3 or 3’ and 5 or
5’), and at least one para chlorine (positions 4 or 4’) (Sable & Schantz, 2006). Such
congeners are called coplanar congeners and are similar in structure to dioxins.
However, when chlorines bind to both ortho positions (i.e., positions 2 and 2’ and/or 6
and 6’) the chlorines repel each other and the molecule takes on a noncoplanar
configuration (Faroon, Jones, & de Rosa, 2000). As such, these congeners are often
referred to as noncoplanar, or ortho-substituted, congeners. PCBs typically exist in the
environment as mixtures of coplanar and, mostly, noncoplanar congeners (Hansen, 1999).
The stability of PCBs makes them an environmental toxin, as these compounds
settle into sediment and do not readily degrade. When PCBs are ingested by human

2

populations, via consumption of exposed fish, cattle, and poultry, a body-burden of
toxicity develops that can affect the developing embryo and fetus of a pregnant
individual. Exposure from mother to offspring also occurs during lactation, as PCBs
readily accumulate in breast milk (Faroon et al., 2000; Hansen, 1999; Jacobson, Fein,
Jacobson, Schwartz, & Dowler, 1984). Because of the persistent and harmful exposure
of PCBs to world-wide populations, studying the effects of exposure to the toxin is
critical to public health.
How Exposure Occurs
Industrial use of PCBs and the subsequent run-off of industrial waste containing
PCBs have affected virtually every country. In the United States, one representative
source of PCB contamination is the Fox River in Northeastern Wisconsin; the toxicity of
this waterway is particularly troublesome due to the extent to which families in the area
rely upon fishing from this river as a way of life. When a man-made toxin as stable as
PCBs gets into an ecosystem, the toxin can bioaccumulate (Hansen, 1999). Typically, it
settles into the fine sediment of waterways, where it is then taken up by small organisms,
which are then eaten by larger organisms, and so on. Humans, in turn, eat the
contaminated fish and are thus also exposed to PCBs.
Kostyniak et al. (2005) formulated a mixture containing the various 209 PCB
congeners found within samples of contaminated fish from the Fox River to be used for
dosing laboratory animals in experimental studies. In contrast to conducting a study in
which animals are exposed to one type of PCB or to a commercial PCB mixture, using a
mixture of congeners found in a contaminated food source in experimental studies is
more applicable to the type of exposure that typically occurs in humans. Thus, to ensure

3

that findings from laboratory studies could be more directly applied to the human
population, this environmentally relevant mixture of PCB congeners was created for oral
dosing in research animals.
Neurotoxicity of PCBs
Several empirical studies over the last twenty years have enhanced the
understanding of how perinatal exposure to PCBs is hazardous to biological systems
throughout the lifespan. As reviewed above, exposure to PCBs is toxic to several bodily
systems including the nervous system. The disruption of brain dopamine (DA)
neurotransmission following exposure to PCBs has been consistently reported in the
literature. Reviews (Faroon et al., 2000; Fonnum & Mariussen, 2009) note that
alterations in DA levels, caused by disruptions to the elements needed for
neurotransmission, are commonly reported in rats and monkeys following PCB exposure.
There are direct effects of exposure to PCBs on several steps of DA
neurotransmission, including the synthesis, storage, release and reuptake of DA. For
example, a study conducted by Chishti, Fisher, and Seegal (1996) using an
environmentally relevant mixture designed to mirror the congener profile found in
contaminated Great Lakes salmon found direct effects of exposure to PCBs on the
storage and release of DA. Seegal and Shain (1992) reported that developmental
exposure to PCBs inhibits the function of a) the enzyme tyrosine hydroxylase which is
the rate-limiting enzyme involved in DA synthesis, b) the dopamine transporter (DAT)
which is a protein involved in DA reuptake, and c) the vesicular monoamine transporter
(VMAT) which is a protein involved in DA vesicular packaging in the presynaptic
neuron. It is important to note that DA is not the only neurotransmitter system affected
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by PCB exposure. However, the effect of PCB exposure seems to be most selective for
DA and its transporters as opposed to serotonin (SE) or norepinephrine (NE) and their
respective transporters (Faroon et al., 2000; Fonnum & Mariussen, 2009). Likewise,
alterations in typical glutamate and GABA neurotransmission following PCB exposure
are also minimal (Fonnum & Mariussen, 2009).
The Role of the Medial-PFC on Inhibitory Control
In vivo studies have reported alterations in brain DA levels that seem to depend
on the type of PCB exposure and when in the lifespan exposure occurs. For example,
perinatal exposure to the commercial PCB mixture Aroclor 1016 increased DA tissue
levels in samples dissected from several brain regions including the substantia nigra,
caudate nucleus, and nucleus accumbens (NAcc) in rats (Seegal, 1994). Perinatal
exposure to individual PCB congeners in rodents had opposite effects on DA
concentrations with exposure to the ortho-substituted (i.e., non-coplanar) congener PCB
47 causing a significant decrease in DA tissue concentration in the caudate nucleus and
frontal cortex, while exposure to coplanar congener PCB 77 resulted in an increase in DA
tissue levels in these same brain regions (Seegal, Brosch, & Okoniewski, 1997). It is
important to note that non-coplanar PCB congeners typically represent the bulk of human
exposure (Hansen, 1999). Following adult exposure, mixtures of mostly non-coplanar
PCB congeners have been shown to decrease DA tissue concentrations in the striatum of
rats (Seegal, Okoniewski, Brosch, & Bemis, 2002) and non-human primates (Seegal,
1996; Seegal, Bush, & Brosch, 1991). In vitro studies done in synaptosomes indicated
increased DA release following exposure to Aroclor 1254 (Mariussen & Fonnum, 2001)
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In the current study, we focused on DA dysfunction in the medial prefrontal
cortex (mPFC) because there is substantial evidence from animal studies (Brake,
Sullivan, & Gratton, 2000; Sable, Eubig, Powers, Wang, & Schantz, 2009; Schoffelmeer
et al., 2011; Sokolowski & Salamone, 1994) that suggest a link between DA functioning
in this area and inhibitory control performance. Inhibitory control is the ability to inhbit a
response when eliciting a response is not appropriate or beneficial. Deficits in inhibitory
control have consistently been found following exposure to PCBs in humans (Stewart et
al., 2003; Stewart et al., 2006) non-human primates (Rice, 1998), and rodents (Sable et
al., 2009) when tested on inhibitory control tasks, such as a differential reinforcement of
low rates (DRL) of responding task. Furthermore, animal studies have shown that DA
depletion in the mPFC substantially impairs DRL performance (Peterson, Wolf, & White,
2003; Sokolowski & Salamone, 1994). DRL is an operant behavioral task wherein
reponses must be withheld until a set period of time has elapsed in order to earn a
reinforcer. If a response is elcicited too early and is not inhibited for the set time period,
the timer resets and another equal time period must elapse before a response-dependent
reinforcer can be earned. Poor performance on this task is an indicator of inhibitory
control problems.
Dopamine and Inhibitory Control
A number of other studies have demonstrated the importance of DA in the PFC on
various types of executive function, including inhibitory control. A review by Robbins
and Arnsten (2009) illustrates that monoamines, including DA, affect behavior on a
number of executive functioning tasks, and that both too much and too little DA within
PFC impair performance. For example, a study conducted by Grégorie, Rivalan, Le
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Moine, and Dellu-Hagedorn (2012) found that both inhibitory control performance and
expression of DA D1 receptors in regions of PFC in rats were reduced in a dosedependent manner following administration of d-amphetamine – a drug known to
increase synaptic DA by reversing the DA transporter (Kahlig & Galli, 2003). On the
other hand, Sokolowsi and Salamone (1994) used 6-hydroxydopamine (6-OHDA) lesions
to deplete DA in mPFC and found that performance on a DRL task was impaired.
Similarly, Peterson et al. (2003) also determined impaired DRL performance in rats
during amphetamine withdrawal – an effect argued to occur due to decreased DA
function in the mPFC. Like Sokolowski and Salamone (1994), Sable et al. (2009) found
a similar disruption in DRL performance in rats that had been perinatally exposed to an
environmentally relevant mixture of PCBs. Rice (1998) also found impairments on DRL
performance in monkeys dosed from birth to 20 weeks of age with a PCB mixture
representative of the PCBs typically found in human breast milk. These deficits in DRL
performance are believed to result from depleted DA in mPFC caused by perinatal PCB
exposure (Sable et al., 2009).
The PCB levels of human populations that live near the Fox River and depend
upon fishing as a way of life have been studied. As part of a series of studies conducted
by the Fox River Environment and Diet Study (FRIENDS) to determine the effects of
eating contaminated fish from this waterway, Schantz et al. (2010) discussed a link
between PCB exposure and levels of attention deficit hyperactivity disorder (ADHD; a
disorder that is often characterized by DA dysfunction and inhibitory control problems)
in children of parents who regularly consumed fish from the Fox River. These results
lend support to previous findings reporting a link between exposure to PCBs and the
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development of inhibitory control problems. The question as to the neurological
underpinnings of the inhibitory control problems found in these children remains
unanswered. One limitation with the PCB epidemiological studies is the inability to
examine the effectiveness of a DA agonist injected directly in mPFC to improve DA
neurotransmission and correct the inhibitory control deficits in PCB-exposed individuals.
Laboratory studies, wherein DA neurotransmission can be intentionally manipulated, are
thus of great value to better understand the relationship among PCB exposure, DA and
mPFC dysfunction, and inhibitory control deficits. Given our interest in the role of the
mPFC in inhibitory control, the DA agonist bupropion was directly administered into the
mPFC in an attempt to facilitate dopaminergic transmission and promote recovery of
inhibitory control function.
Bupropion and Dopamine
PCB exposure has been shown to inhibit the dopamine transporter (DAT) and
decrease DAT expression (Bemis & Seegal, 2004; Caudle et al., 2006; Fonnum &
Mariussen, 2009; Lyng, Snyder-Keller, & Seegal, 2007; Richardson & Miller, 2004).
The DAT aids in the regulation of DA neurotransmission by recycling DA from the
synapse in a process known as reuptake. When the DAT is inhibited, DA remains in the
synapse for a longer period of time, thereby promoting synaptic neurotransmission.
However, constant inhibition of DAT, as found in animals perinatally exposed to PCBs,
has been shown to lead to transient changes in DA release over time likely due to endproduct inhibition (Huang & Zhan, 2007). Specifically, studies have demonstrated that
exposure to PCBs initially resulted in increased synaptic DA, which over time led to
decreased synaptic DA as measured by microdialysis (Seegal et al.,, 2002. Research has
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shown that PCB induced DAT inhibition, and subsequent dysfunction in DA
neurotransmission, leads to an eventual reduction in DA release due to the activity of DA
autoreceptors on the presynaptic cell (Seegal et al., 2002). PCB exposure has also been
shown to inhibit and decrease expression of the VMAT2 (Bemis & Seegal, 2004; Caudle
et al., 2006; Caudle et al., 2007; Lyng & Seegal, 2008; Lyng, Snyder-Keller, & Seegal,
2007; Richardson & Miller, 2004), which is a protein that is involved in the sequestering
of free DA into vesicles for later release into the synapse (Seegal & Shain, 1992).
In theory, synaptic DA in PCB-exposed animals could potentially be augmented
by drugs that act as either a DAT inhibitor or a VMAT2 agonist. By preventing DA
reuptake and promoting vesicular packaging of DA for later release, synaptic DA should
increase and performance on an inhibitory control task should improve. To examine this
issue, the drug bupropion was selected for use because bupropion functions as a DA
agonist by both inhibiting DAT (Learned-Coughlin et al., 2003) as well as increasing the
function of VMAT2 (Rau et al., 2005). As can be seen in figure 1B (adapted from
Latawiec et al., 2010), the structure of bupropion is very similar to that of DA (figure
1C). Microdialysis procedures reveal that administration of bupropion increases synaptic
DA levels in both the mPFC (Kusaka, Kitazumi, & Nakayama, 2006) and in striatum
(Kitamura et al., 2010; Nomikos, Damsma, Wenkstern, & Fibiger, 1990), making this an
ideal agonist to use in this study.
Hypotheses of Current Study
In sum, it is well known that DA depletion within mPFC leads to poor
performance on an inhibitory control task. It is also well known that PCB exposure leads
to poor inhibitory control performance. What is not well established is whether or not the
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inhibitory control problems found following PCB exposure are mediated by DA
depletion in mPFC. The purpose of this study was to examine the effects of
microinjection the DAT inhibitor/VMAT2 agonist bupropion into the mPFC on
inhibitory control performance in adult rats that were perinatally exposed to an
environmentally relevant PCB mixture (i.e., the Fox River Mix). Inhibitory control
performance was measured using a DRL task (described previously). Based on previous
research, a deficit in DRL performance resulting from perinatal PCB exposure was
expected. As the deficit in DRL performance is believed to occur due to decreased DA
neurotransmission in the mPFC, it was hypothesized that the DAT inhibitor bupropion
administered bilaterally into the mPFC would improve inhibitory control performance in
PCB-exposed animals.
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Chapter 2: Methods
Subjects
Eighteen nulliparious female Long-Evans rats (Harlan Barrier 202A;
Indianapolis, IN) were housed in standard rat shoe-box caging containing Harlan Teklad
Laboratory Grade Sani-Chips bedding. All rats were given water ad libitum and fed a
diet of Harlan Teklad 2020X rat chow, which is a high-protein, low phytoestrogen diet, in
order to maintain overall rodent health and to ensure that the pregnant females were able
to support their litters. All rats were kept on a regular 12 hour light/dark cycle (lights on
at 0730 hr). Rats were dosed, weighed, tested, and fed at the same times each day, during
the lights-on phase of the light cycle.
Exposure
The female rats were delivered to the housing facility and housed individually
upon arrival. Dosing procedures were akin to those used by Sable et al. (2006, 2009,
2010). Each female was weighed and given an undosed vanilla wafer cookie to acclimate
the rats to eating this novel food item. The stock solution of the Fox River PCB mixture
(Kostyniak et al., 2005) was diluted with corn oil to make three dosing solutions: 0 µl/ml
PCBs (corn oil only), 7.5 µl/ml PCBs, and 15.0 µl/ml PCBs. The stock solution was
pipetted onto one-half of a vanilla wafer cookie at a volume of 0.4 mL/kg to yield final
doses of 0, 3, and 6 mg/kg/day. It is known that at the highest PCB dose (6 mg/kg/day)
rats show reductions in postnatal body weight, and that these effects mirror the effects
found on postnatal weight gain in children perinatally exposed to PCBs (Govarts et al.,
2012; Kostyniak et al., 2005). As such, the doses chosen for the current study appear to
be phenotypically relevant. Females were weighed daily, and these weights were used to
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determine the amount of dosing solution applied to the cookie each day. The female rats
were randomly divided into one of the three PCB dose groups. The concentration of
PCBs in the dosing solutions were verified via analytical methods prior to dosing and
stored in a refrigerator until used.
For 28 days, the females were presented with their respective PCB dose (via the
dosed cookie) in order to develop a PCB body burden. Consumption of the cookie was
visually confirmed each day. On day 29, each female rat was paired with one unexposed
male Long-Evans rat (same barrier from Harlan). Breeding pairs remained together for 8
days, with the female being removed for PCB dosing (i.e., a maximum of 20 minutes
each day) as previously described. After breeding, the pairs were separated and females
was continued to be dosed during gestation (roughly 21 days) and lactation (21 days).
Thus, the offspring of each dam were exposed to PCBs via gestational and lactational
PCB transfer. Because PCBs pass very readily through the placenta and into breast milk,
all pups born to directly-exposed dams were assumed to be equally exposed. However,
the number of pups supported by each dam after birth was controlled by eliminating
litters that were too small and culling large litters. Litters that had fewer than eight pups
were eliminated. Large litters were culled to 10 pups, and extra pups cross-fostered into
litters of the same age and exposure group that had at least eight pups to increase these
litters to 10 pups. Cross-fostered pups were marked by ear clip and not used for later
testing. Weaning occurred on postnatal day (PND) 21, at which time exposure to the
toxin ended. At weaning, one male/female pair from each litter were sacrificed (when
available) to determine physiological measures of toxicity. A second male/female pair
was kept for behavioral testing which began around PND 100.
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Physiological measures including the dam liver weight, dam implantation sites,
and brain:body weight, liver:body weight, and thymus:body weight ratios in the pups at
the time of weaning were determined to confirm PCB exposure (see Sable et al., 2010).
Other general developmental outcomes, including the percent gestational and lactational
weight gain, and postnatal body weights of the pups on PND 0, 7, 14, and 21 were also
collected. Weaned rats were pair- or triple-housed according to cohort and exposure
level prior to surgery and were single-housed following surgery.
Surgery
After a behavioral baseline level of performance had been established (see
below), each rat was bilaterally implanted with stainless-steel guide cannulae aimed at
the mPFC using aseptic procedures. The guide cannulae were 26 gauge (Plastics One;
Roanoke, Virginia) cut to 5 mm below the pedestal. The dummy cannula and implanting
cannula (both 33 gauge) were also from Plastics One and cut to fit the guides without
further projection. The implanting cannulae were placed inside the cannula guides during
surgery to prevent occlusion of the guide cannulae during implantation. The dummy
cannula served a similar purpose after the guides were implanted, and were only removed
during later drug microinjection.
Sedation was accomplished via a mix of oxygen and Butler Isothesia isoflurane
(1%) using a Surgivet Classic T3 Isoflurane delivery system (Dublin, Ohio). Surgeries
were performed using a KOPF Instruments Bilateral Stereotaxic Apparatus with the nose
bar (equipped with anesthesia nose cone) set 3.3 mm below interaural zero. With the
skull exposed, cleaned, and dried, three skull screws (Plastics One; Roanoke, Virginia)
were placed in the skull posterior to bregma to anchor the dental sealant that was applied
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later. Measurements were taken from bregma in two dimensions (anterior/posterior and
medial/lateral) with the arms at a 10° angle. The cannula guides were implanted +3 mm
A/P and +1.4 mm M/L to bregma and lowered -2.7 mm ventral from the skull surface
through burr holes drilled through the skull. Kerr Herculite Ultra A2 Dentin dental
sealant was applied around the skull screws and cannulae to create a cap that was cured
with a Henry Schein CU1000 curing light. When the surgery was complete, rats were
removed from the stereotax and given subcutaneous injections of baytril (an antibiotic,
2.5 mg/kg) and carprofen (an anti-inflammatory, 2.5 mg/kg) and allowed 24 hours for
recovery with an additional injection of carprofen on recovery day.
Drugs
Bupropion hydrochloride (Tocris, batch number 1A/9546) in doses of 0.02
mg/mL, 0.12 mg/mL, and 0.24 mg/mL was mixed into a vehicle consisting of a 1:10
double distilled H2O solution:physiological saline. Doses were selected based on the
findings by Nomikos et al. (1990) who used reverse microdialysis to confirm that DA
levels in rat striatum were increased by 500% - 1400% following local infusions of doses
of bupropion at 100 and 1000 µM, respectively, within 10 min after the start of bupropion
infusion. The smallest dose chosen for the current study was 0.02 mg/ml (= 724.113
µM), which is within the range found to increase DA release. The larger doses of
bupropion, 0.12 mg/mL, and 0.24 mg/mL (=4.3447 µM and 8.6894 µM, respectively),
were chosen in an attempt to effectively overcome the presumed deficit in DA
neurotransmission in PCB-exposed rats. These larger doses were presumed to be
effective as microinjections of 5 and 15 µg/side of bupropion into the nucleus accumbens
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of rats also elicited an increase in the release of DA as measured by microdialysis
(Kitamura et al., 2010).
Small aliquots (1 mL) of vehicle and each bupropion dose were stored in a -80°C
Revco Ultima II freezer until the day of use. Aliquots not used within 30 days of
preparation were discarded.
Apparatus
Behavioral testing was conducted in 10 automated operant testing chambers (Med
Associates; St. Albans, VT). These chambers were both sound-reducing and ventilated.
On one wall of the chambers were two retractable response levers, each 7 cm above the
floor of the chamber and 5.7 cm from the midline of the wall. Two cue lights were also
present in the operant chambers, 5.7 cm above the response levers. A house light was
situated on the wall opposite the levers. A food magazine was situated between the
response levers. All operant programs were controlled via a PC equipped with Med–PC
IV software (Med Associates) and all data generated was stored on the same computer
and backed up to a server in a remote location.
Procedure
When the offspring were 90 days old, they were placed on an IACUC-approved
food deprivation schedule of 85% of their free-feeding weight (to motivate the rats to
work for food rewards), which persisted until the end of the experiment. At around 100
days old, rats began testing in the operant chambers. Operant testing occurred six
days/week, and food deprivation procedures were implemented each day of the week.
Autoshaping and fixed ratio training. During autoshaping, both levers were
made available to the rat, and every press on either lever resulted in the delivery of a food
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reward. If no lever press occurred within 3 minutes, a free 45 mg reward pellet (Bio
Serv; Frenchtown, New Jersey) was dispensed into the food magazine to entice the rat to
explore the operant box and to press the levers. The rats had a maximum of one hour to
earn 100 pellets, including free pellets. Rats were maintained on autoshaping until 100
lever presses occurred in a session and zero free pellets were dispensed – typically two to
three sessions.
Since both levers were made available during autoshaping, a preference for one
lever may have occurred. To eliminate this type of preference, rats underwent three days
of fixed ratio (FR) training. At the start of each FR session, the right response lever only
was presented and the right cue light illuminated. Each lever press resulted in the
delivery of a food pellet into the food magazine. After five food rewards were dispensed
by pressing the right lever, the cue light over this lever was extinguished, the lever
retracted, and the opposite lever and cue light was activated. After five reinforcers were
earned, the active lever switched back to the other lever. This process was repeated until
100 food rewards were earned or until one hour had elapsed. FR training lasted for three
sessions.
Differential reinforcement of low rates (DRL). Immediately following the
three days of FR training, rats were trained on a DRL task (DRL 1) in which only the
right lever was presented. DRL 1 required rats to learn that they had to make one press to
initiate a trial and a second lever press 1 sec later in order to earn a food pellet. No
reinforcer was delivered if the second response occurred within 1 sec of the first. The rat
was required to press the response lever to initiate another trial and delivery of a food
pellet only occurred if the full 1 sec elapsed before the response lever was pressed again.
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Each session continued until 90 min elapsed or the rat earned 200 reinforcers. After two
sessions of DRL 1, the rats progressed through two sessions of DRL 5 and two sessions
of DRL 10, where rats had to wait 5 and 10 sec between lever presses, respectively, in
order to successfully earn a food reinforcer. Finally, rats were tested on a DRL 15
program in which the rat had to wait 15 sec between lever presses to earn a reinforcer.
DRL 15 testing took place over 35 days to promote steady-state performance and
establish “baseline” performance prior to surgery.
Bupropion drug challenge. All rats were given 24 hours to recover from surgery
before beginning microinjections. Microinjections were done using a Harvard Apparatus
Microinjection Pump with a 10 μL Hamilton Syringe (24 gauge). The rats were first
given a 3-day series of mock injections to become acclimated to the microinjection
procedure. During the mock injections, the dummy cannulae were removed and the
microinjection cannulae (33 gauge) inserted into each guide to protrude 1 mm below the
bottom of the guides. The pump was driven for 30 sec but no vehicle or drug solution was
administered. The microinjectors remained in place for a minimum of 30 sec before they
were removed and the dummy cannualae were replaced. Rats were tested on DRL 15
following the second and third mock injection. On the following days, microinjections of
bupropion were administered immediately prior to DRL 15 testing. Three replicates of
each drug dose were given (0 μg/side, 0.01 μg/side, 0.06 μg/side, 0.12 μg/side) in
ascending order (one dose/day). Microinjections were given at a rate of 1 μL/min.
Microinjectors remained in place for another 30 sec to allow for diffusion before being
removed, after which the dummy cannula were replaced, and the rat was immediately
placed in the operant chamber for DRL 15 testing.
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Implantation site verification. After completing all three replicates for each of
the four doses of bupropion, rats were euthanized via overexposure to carbon dioxide.
Methylene blue dye was then bilaterally microinjected into the mPFC in order to verify
the locations of drug microinfusion. The brain of each rat was then harvested and stored
overnight in a 20C freezer. The following day, brains were moved to a cryostat set at
20C and slices at a thickness of 20 microns were collected on slides for examination to
determine if the microinjections occurred in the mPFC. Images from (Paxinos &
Watson, 1998) slicing guide depicting the target area of prelimbic mPFC, ranging from
+3.72 mm to +2.52 mm anterior to bregma, was used during slicing to confirm correct
placements of cannulae guides and microinjectiors. If the microinjection sites did not
occur in this target area, data from the rat was not included in the analyses.
Data Analysis
A list of all of the dependent measures that were analyzed is included in Table 1.
All data analyses were conducted via SPSS for Windows, version 20.
Physiological measures. The liver weight of the dam, number of implantation
sites, and the percent gestational and lactational weight gain were analyzed via one-way
between-subjects ANOVAs for PCB exposure group. The organ:body weight ratio data
were analyzed separately for brain, liver, and thymus via 3 x 2 (PCB group x sex) mixed
ANOVAs where PCB exposure group was a between-subjects factor and sex (nested
within litter) was a repeated-measures factor. The data on postnatal weight gain was
similarly analyzed but also included day (PND 0, 7, 14, and 21) as an additional repeatedmeasures factor.

18

DRL 15.
General learning outcomes. The ratio of reinforced to non-reinforced lever
presses and the number of reinforcers delivered were used as overall measures of
performance. A higher ratio of reinforced:nonreinforced presses and a higher number of
reinforcers earned were indicative of better performance. These data were analyzed
separately via 3 x 2 x 7 (PCB exposure group x sex x 5-day block) mixed ANOVAs
where PCB exposure group was a between-subjects factor and sex (nested within litter)
and 5-day block were repeated-measures factors.
Response pattern analysis. Each lever press that was made during testing in an
attempt to earn a reinforcer (i.e., those that are not made to initiate a trial), were
categorized into one of eight inter-response time (IRT) bins each 2.49 sec in size (e.g., 02.49 sec, 2.50 – 4.99 sec, 5.00 – 7.49 sec, 7.50 – 8.99 sec, 9.00 – 12.49 sec, 12.50 – 14.99
sec, 15.00 – 17.49 sec, >17.50 sec). The number of responses in each bin were then
converted into the proportion of responses falling into each IRT bin, and these data were
analyzed via 3 x 2 x 8 (PCB exposure group x sex x IRT bin) mixed ANOVAs where
PCB exposure group was a between-subjects factor and sex (nested within litter) and IRT
bin were repeated-measures factors.
Bupropion drug challenge.
Percent change in general learning outcomes from DRL 15 baseline. DRL
performance averaged across the final five days of pre-surgery DRL 15 performance was
considered baseline DRL performance. The effect of bupropion on DRL performance
was determined by first averaging performance across the three replicates of each
bupropion dose and then expressing the average performance at each bupropion dose as a
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percent change from pre-surgery DRL baseline performance for each rat using the
following formula:

Percent change = [(performance for each bupropion dose-baseline performance) /
baseline performance] * 100

The percent change in the ratio of reinforced:nonreinforced responses and
reinforcers earned were analyzed with 3 x 2 x 4 (PCB exposure group x sex x bupropion
dose) mixed ANOVAs where PCB exposure group was a between-subjects factor, while
sex (nested within litter) and bupropion dose were repeated measures factors.
Percent change in response pattern from DRL 15 baseline. The proportion of
responses within each IRT bin were averaged across the replicates of each bupropion
dose and then expressed as a percent change from DRL baseline using the following
formula:

Percent change = [(proportion of responses in each ITR bin for each bupropion
dose – proportion of responses in each IRT bin during
baseline/proportion of responses in each IRT bin during
baseline] * 100

The percent change in the proportion of responses within each IRT bin was
analyzed using 3 x 2 x 4 x 8 (PCB exposure group x sex x bupropion dose x IRT) mixed
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ANOVA. For this analysis, exposure group was a between-subjects factor, while sex,
bupropion dose, and IRT bin were repeated measures factors.
Additional post hoc analyses were conducted as appropriate to determine the
nature of significant main effects and interactions found in the previously described
overall omnibus analyses. In particular, when PCB exposure group differences were
found, Dunnett t-tests were conducted. An adjustment to the alpha level was not
incorporated for the Dunnett t-tests because Dunnett post hoc comparisons already
control for the experimental-wise error rate (Maxwell & Delaney, 2000, p. 193).

21

Chapter 3: Results
Physiological Measures
No significant differences were found between PCB exposure groups on dam
liver weight at weaning on PND 21. Likewise, dam gestational and lactational weight
gain, litter size, and percent male/litter also did not significantly differ as a function of
PCB exposure group. There was a main effect of exposure for the percent of live births,
F(2, 15) = 4.919, p = .023. Post hoc Dunnett t-tests revealed the 3 mg/kg/day group was
significantly lower than controls (p = .029; Table 2). A significant PCB exposure x day
interaction was found for pup postnatal weight gain, F(5, 45) = 5.745, p < .001 (Table 3).
Dunnett t-tests revealed that postnatal weight gain was significantly higher for pups in the
0 mg/kg/day group than pups in both the 3 mg/kg/day and the 6 mg/kg/day PCB exposed
pups on PND 7 (p = .001 and p < .001, respectively), PND 14 (p = .005 and p = .001,
respectively), and PND 21 (p = .003 and p = .012, respectively). Significant effects were
also found for pup organ:body weight ratio at weaning on PND 21 (Table 4). A
significant main effect of PCB exposure group was found for pup brain:body weight
ratio, F(1, 2) = 6.152, p = .011, liver:body weight ratio, F(1, 2) = 35.715, p < .001, and
thymus:body weight ratio, F(1, 2) = 13.562, p < .001. Dunnett t-tests conducted on each
organ:body weight ratios revealed a significantly lower ratio for the 0 mg/kg/day PCB
exposure group compared to both the 3 mg/kg/day (p = .048, p < .001, and p = .007 for
brain, liver, and thymus ratios, respectively) and 6 mg/kg/day (p = .007, p < .001, and p <
.001 for brain, liver, and thymus ratios, respectively) PCB exposure groups (Table 4).
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DRL 15
General learning outcomes. A significant main effect of PCB exposure group
was found for reinforced:nonreinforced responses on the DRL 15 data collected prior to
surgery, F(1, 2) = 6.414, p = .010. Dunnett t-tests reveal that the 3 mg/kg/day PCB group
had a significantly lower ratio than the 0 mg/kg/day PCB group (p = .005; Figure 2). The
difference between the 0 mg/kg/day PCB group was not significant (p = .084). There
were no significant exposure-related effects found in number of reinforcers earned, F(2,
15) = 2.973, p = .082 (Figure 3).
Response pattern analysis. No significant exposure-related differences were
found in the IRT data. There was, as expected, a significant main effect of IRT bin, F(7,
105) = 36.513, p < .001, with the distribution of the proportion of responses within the 8
IRT bins following a U-shaped curve (see Figure 4).
Bupropion Drug Challenge
Percent change in general learning outcomes from DRL 15 baseline. No
exposure-related effects were observed on the percent change from baseline for
reinforced:nonreinforced responses (Figure 5). Only a significant main effect of
bupropion dose was found following bupropion drug challenge, F(3, 45) = 3.239, p =
.031. The percent positive change from baseline increased with increasing bupropion
dose. There was also a significant main effect of bupropion dose for the percent change
from baseline in reinforcers earned during the bupropion drug challenge, F(3, 45) =
7.541, p < .001 (Figure 6). As bupropion dose increased, the percent increase in the
number of reinforcers earned during baseline also increased.
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Percent change in response pattern from DRL 15 baseline. No exposure
related effects were found for this dependent measure. Only a significant IRT bin x
bupropion dose interaction, F(21, 315) = 3.628, p < .001, and main effect of bupropion
dose, F(3, 45) = 6.299, p = .001, were found in the percent change from baseline for the
proportion of responses that occurred within the eight 2.5 sec IRT bins. Except for the
lowest bin (< 2.5 sec) which showed the opposite effect, increasing dose of bupropion
resulted in a smaller percent increase in the proportion of responses that occurred in each
IRT bin relative to baseline (Figure 7).
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Chapter 4: Discussion
Physiological Outcomes
The numerous physiological significant main effects of PCB exposure group that
were found in this study verify that perinatal dosing of the Long-Evans dams was
successful. These results are also similar to those found in other studies (Sable et al.,
2009; Sable et al, 2010), which increases the reliability of the dosing paradigm used. The
effects of PCB exposure on the weights of the brain, liver, and thymus of the pups
illustrates the dangers that exposure to this toxin can have on developing organ systems.
The health effects to the dams were minimal; the only significant main effect of PCB
exposure was on the percent of live births for the 3 mg/kg/day PCB group dams, and this
finding was guided simply by the fact that all dams from both of the other PCB exposure
groups (i.e., 0 mg/kg/day and 6 mg/kg/day) had 100% live births.
DRL 15
General learning outcomes. The modest difference in the number of reinforcers
earned along with the significant difference found for the ratio of
reinforced:nonreinforced trials indicated that the unexposed 0 mg/kg/day rats had better
performance on the DRL 15 task compared to rats in the 3 and 6 mg/kg/day PCB
exposure groups. As previously mentioned, differences in DRL performance following
perinatal exposure to environmentally relevant PCB mixtures has been reported in prior
studies in rodents (Sable et al., 2009) and monkeys (Rice, 1998). Children exposed to
PCBs also show the same DRL deficits found in laboratory studies (Stewart et al., 2006).
Response pattern analysis. No significant exposure-related effects were found
on the proportion of responses falling within the different IRT bins. It should be noted
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however, that generally speaking, 0 mg/kg/day rats had higher proportions of responses
in the longer, successful IRT bins (i.e., 15.0 – 17.5 sec and > 17.5 sec) and lower
proportions of responses in shorter, unsuccessful IRT bins (i.e., < 2.5 sec through 15.0
sec) than both the 3 mg/kg/day and 6 mg/kg/day rats. As expected, the distribution of
responses in each of the IRT bins followed a U-shaped pattern with higher proportions of
responses in both the lowest and highest IRT bins. Sable et al. (2009) found similar
results for the 0, 3, and 6 mg/kg PCB exposure groups relative to what was found in this
study.
Bupropion Drug Challenge
General learning outcomes. A significant effect of bupropion dose on the
percent change from baseline in the ratio of reinforced:nonreinforced lever presses and
reinforcers earned was found. The percent positive change from baseline performance
increased with increasing bupropion dose. It is important to consider, however, that the
significant effect of bupropion dose was potentially confounded by recovery effects since
the three replicates of each dose of bupropion were microinjected in ascending order after
surgery. Thus, it is not entirely clear if the doses of bupropion alone augmented
performance, or if the effect seen was in fact really due to performance improvements
with increasing recovery days post-surgery. It is equally important to note, however, that
all three exposure groups had the same surgery and (as such) were facing the same
potential problems with post-surgery performance.
Response pattern analysis. The potential confound of recovery noted previously
is further emphasized within the significant IRT bin x bupropion dose interaction on the
percent change from baseline in the proportion of responses occurring within the IRT
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bins. The largest changes from baseline across the IRT bins (excluding the first and last
IRT bins) occurred after microinjection of the lowest bupropion dose (0 µg/side).
Specifically, there was a rather profound increase in the proportion of responses falling
within the shorter bins that were less than the 15 sec IRT required for reinforcement. On
the other hand, the smallest changes from baseline occurred following administration of
the highest bupropion dose (0.12 µg/side) (i.e., the increases in the percent of responses
falling within the IRT bins that were less than 15 sec were not as substantial following
the highest dose of bupropion compared to 0 µg/side. Thus, it is unclear as to whether or
not performance on the task increased as a function of increasing bupropion dose or if the
interaction represents a day of testing (i.e., recovery effect) confound.
Effectiveness of Bupropion Treatment
This study did not find strong evidence that the doses of bupropion were effective
at reversing the suspected deficits in DA neurotransmission caused by perinatal exposure
to PCBs. Obvious improvements in DRL performance following bupropion
administration were not found in rats perinatally exposed to PCBs.
Limitations
Effects on NET vs. DAT. The effectiveness of bupropion to increase synaptic
DA levels was not directly measured in this study, only the potential indirect effects of
increasing DA neurotransmission in PCB-exposed rats as measured by DRL performance
was examined. As such, the exact effect that the doses of bupropion used in this study
had on improving DA neurotransmission in mPFC of rats exposed to the Fox River PCB
mixture remains uncertain. Based on the negligible changes in DRL performance, it
appears that bupropion did not differentially increase DA neurotransmission in PCB-

27

exposed rats. Another possible scenario is that bupropion did effectively inhibit DAT
and augmented VMAT2 action, but these effects were mitigated by an overarching PCBinduced decrease in DA synthesis (Seegal & Shain, 1992). One concern with the use of
bupropion is the effects that this drug has on the NE transporter (NET) in addition to
inhibiting DAT and augmenting VMAT2 expression (Dwoskin, Rahut, King-Pospisil, &
Bardo, 2006). The increase in NE neurotransmission following microinjections of
bupropion may have influenced the results found in the present study, as increases in NE
neurotransmission have been found to lead to improved performance on inhibitory
control tasks (O’Donnell, Marek, & Seiden, 2005). Thus, while bupropion was chosen
for this study due to the fact that it was not only influentially selective for DAT, but also
for VMAT2, it may have been more advantageous to choose a drug that was more
selective for DAT as the effects on NET would have been avoided.
Bupropion dose order. Using a balanced Latin square to determine the order of
administration for the different bupropion doses would have eliminated the recovery
effect confound. However, even this approach represented the potential for carry over
effects in DAT inhibition and VMAT2 function caused by microinjections of high doses
of bupropion to injections of low doses of bupropion that may have made it difficult to
adequately assess differences in bupropion dose across PCB exposure groups. As
behavior was expected to return to pre-surgery baseline levels by the time bupropion
doses were administered, avoiding potential carry over effects was considered to be a
more serious concern when the study was designed. However, the stereotaxic surgery
and the microinjection procedure that followed appeared to be more stressful and
disruptive to inhibitory control performance than expected. The decrease in inhibitory
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control performance seen in all PCB-exposure groups due to the cannulation surgery may
have made it more difficult to determine how bupropion differentially affected
performance across PCB exposure groups.
Future Research
It may well be the case that the only way to enhance DA neurotransmission
following perinatal exposure to PCBs is not to attempt to increase synaptic DA via
presynaptic mechanisms, but rather to microinject DA agonists that mimic the actions of
DA on post-synaptic DA receptors. Future studies are planned to investigate the effects
of both DA D1 and D2 receptor agonists microinjected into the mPFC on DRL
performance. These future studies should attempt to ensure DRL performance postsurgery returns to baseline levels prior to drug microinjection, particularly if the doses
used will be administered in ascending order in so as to avoid the confound of postsurgery recovery on DRL performance.
Implications and General Conclusions
The results from this study lend support to the growing literature regarding the
negative effects of PCB exposure on inhibitory control performance as rats perinatally
exposed to PCBs had impaired DRL performance. This study was conducted to
determine whether or not microinjections into mPFC of the indirect DA agonist
bupropion would improve inhibitory control performance in rats following perinatal
exposure to PCBs. The results of this study indicated that bupropion was not effective at
improving inhibitory control performance in rats perinatally exposed to PCBs. As
previously mentioned, there is a high prevalence of cases of ADHD in PCB exposed
children (Schantz et al., 2010). Understanding the mechanism responsible for PCB-
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induced deficits in inhibitory control performance must occur before pharmacotherapies
to improve performance in those who are heavily exposed can be developed. In addition,
education regarding the deleterious effects of PCB exposure must also continue in an
attempt to minimize exposure, promote cleanup of contaminated areas, and protect public
health.
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Ortho chlorines = 2, 2’, 6, 6’
Meta chlorines = 3, 3’, 5, 5’
Para chlorines = 4, 4’

Figure 1A. The chemical structure of PCBs (from Faroon et al., 2000)

Figure 1B. The chemical structure of bupropion (from Preskorn & Othmer,1984)

Figure 1C. The chemical structure of dopamine (from Latawiec et al., 2010)
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Figure 2. Reinforced:Non-reinforced presses by exposure group prior to surgery.
It was hypothesized that PCB exposure would impair inhibitory control performance as
measured on a differential reinforcement of low rates of responding (DRL) 15 second
task. The hypothesis was supported as PCB exposure decreased the ratio of
reinforced:nonreinforced trials. *p=.005. +p=.084.
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Figure 3. Reinforcers earned over 5 day testing blocks prior to surgery for both
males and females.
It was hypothesized that PCB exposure would decrease the number of reinforcers earned
on a differential reinforcement of low rates of responding (DRL) 15 second task. While
the data suggests rats exposed to PCBs did earn fewer reinforcers on the task relative to
controls, the main effect of exposure only approached significance, p=.082.
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Figure 4. Proportion of responses in each 2.5 sec IRT bin prior to surgery.
The proportion of responses in each inter-response time (IRT) bin during a differential
reinforcement of low rates (DRL) 15 second task as a function of PCB exposure group for
male (top) and female (bottom) offspring. No PCB-exposure related differences were
found.
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Figure 5. Percent change from baseline for reinforced:nonreinforced presses during
bupropion drug challenge post-surgery for both males and females.
The percent change from pre-surgery baseline for the number of reinforced to
nonreinforced trials across bupropion microinjection doses for the male (top) and female
(bottom) offspring. No PCB exposure-related significant differences were found.
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Figure 6. Percent change from baseline for the number of reinforcers earned
during bupropion drug challenge post-surgery by exposure group.
The percent change from pre-surgery baseline for the number of reinforcers earned across
bupropion microinjection doses for the male (top) and female (bottom) offspring. No
significant PCB-exposure related effects were observed.
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Figure 7. Percent change from baseline in proportion of responses in the eight
2.5 sec time bins during bupropion drug challenge.
No significant exposure-related effects were found on the percent change from baseline
in the proportion of responses falling within each of the eight 2.5 sec interresponse time
(IRT) bins following bupropion microinjection.
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Table 1
Dependent Variables to be used in Data Analyses
________________________________________________________________________
Type of Measure
Dependent variables
________________________________________________________________________
Physiological
From Dam

a) Liver weight
b) Implantation sites
c) Percent gestational weight gain
d) Percent lactational weight gain

From PND 21 pups
(one male/female/litter)

a) Brain weight:body Weight
b) Liver weight:body Weight
c) Thymus weight:body Weight
d) Postnatal weight gain: PND 0, 7, 14, 21

Behavioral
DRL 15

a) Reinforced:non-reinforced Responses*
b) Reinforcers earned*
c) Proportion of Responses within each 2.5 IRT Bin

Bupropion Drug Challenge

a) Percent Change from baseline in reinforced:nonreinforced responses
b) Percent Change from baseline in reinforcers
earned
c) Percent change from baseline in proportion of
responses within each 2.5 sec IRT bin
________________________________________________________________________
Note. *Presented in 5 day blocks (Final block = DRL Baseline)
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TABLE 2
Reproductive Outcomes of Dams Exposed to 0, 3, or 6 mg/kg/day PCB (Fox River Mix) during Gestation and Lactation
________________________________________________________________________________________________________
PCB Dose

Dam Gestational Dam Lactational
Dam Liver:
Litter
%Male
%Live
Weight Gain (g) Weight Gain (g)
Body Weight (g)
Size
Births
____________________________________________________________________________________________________________
0 mg/kg/day (6 litters) 46.590 ± 1.44
11.869 ± 2.64
0.0542 ± 0.005
14.0 ± 0.78
51.63 ± 3.49
100 ± 0
3 mg/kg/day (6 litters) 41.890 ± 1.50
13.343 ± 1.83
0.0534 ± 0.00
13.5 ± 0.43
55.98 ± 4.12
96.22 ± 1.71*
6 mg/kg/day (6 litters) 43.302 ± 2.83
11.683 ± 2.54
0.0558 ± 0.003
12.0 ± 1.61
51.34 ± 3.78
100 ± 0
____________________________________________________________________________________________________________
Note. Means (± SEM); *p<0.05.
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TABLE 3
Average Body Weight (±SEM) for Pups Born to Dams Exposed to
0, 1, 3, or 6 mg/kg/day PCB (Fox River Mix) during Gestation and Lactation
____________________________________________________________________________________________________________
PND 0
PND 7
PND 14
PND 21
____________________________________________________________________________________________________________
0 mg/kg/day PCB (6 litters)
MALE
5.84 ± 0.20
14.31 ± 0.39
28.57 ± 0.65
43.55 ± 1.29
FEMALE
5.67 ± 0.16
13.95 ± 0.41
28.35 ± 0.70
42.51 ± 1.24
3 mg/kg/day PCB (6 litters)
MALE
5.40 ± 0.13
12.00 ± 0.41
24.34 ± 0.75
36.45 ± 1.38
*
*
FEMALE
5.28 ± 0.21
11.78 ± 0.51
24.14 ± 0.77
29.25 ± 5.29 *
6 mg/kg/day PCB (6 litters)
MALE
5.79 ± 0.17
11.77 ± 0.41
23.33 ± 1.22
35.72 ± 1.79
*
*
FEMALE
5.46 ± 0.11
11.35 ± 0.34
22.77 ± 0.85
33.60 ± 1.28 **
____________________________________________________________________________________________________________
Note. Body weights are in grams; *p<0.01. **p<0.001.
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TABLE 4
Average (±SEM) Organ: Body Weight Ratios on PND 21 for Pups Exposed to
the Fox River PCB Mixture During Gestation and Lactation
____________________________________________________________________________________________________________
PCB Exposure Group
Brain:body weight ratio
Liver:body weight ratio
Thymus:body weight ratio
____________________________________________________________________________________________________________
0 mg/kg/day (6 litters)
MALE
0.0354 ± 0.0011
0.0376 ± 0.0030
0.0044 ± 0.0004
FEMALE
0.0336 ± 0.0010
0.0407 ± 0.0018
0.0045 ± 0.0003
3.0 mg/kg/day (6 litters)
MALE
0.0386 ± 0.0014
0.0638 ± 0.0041
0.0035 ± 0.0002
FEMALE
0.0394 ± 0.0014 *
0.0598 ± 0.0029 ***
0.0036 ± 0.0002 **
6.0 mg/kg/day (6 litters)
MALE
0.0402 ± 0.0017 **
0.0672 ± 0.0028 ***
0.0033 ± 0.0002 ***
FEMALE
0.0412 ± 0.0015
0.0681 ± 0.0037
0.0030 ± 0.0001
____________________________________________________________________________________________________________
Note. Weights are in grams; *p<0.05. **p<0.01. ***p<0.001.
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